We repeated the drug-combination experiment with another primary sample (L826-MLL/AF4) and in accordance with reported literature45 confirmed a combination of DOT1L inhibitor EPZ5676 and ABT-199 (CI=0.39) to be synergistic in MLL rearranged leukaemia (Figures 8c, d and g). The gene discussed is KMT2A; the disease is leukemia.